SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Roche obesity drug trial met main goals on glucose and weight

Roche Holding said its obesity drug candidate met the main objectives of a midstage clinical trial, helping patients reduce blood glucose and body weight, as it looks to enter the weight-loss drug market dominated by Eli Lilly and Novo Nordisk.

RHO

By Adria CalatayudRoche Holding said an obesity drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.The Swiss pharmaceutical company is seeking to enter the weight-loss drug market that Eli Lilly and Novo Nordisk current…

Related stories